

FOR IMMEDIATE RELEASE

Media Contact Information:
NanoPin Technologies
+1 805-680-0377

NanoPin Technologies Announces a Strategic Collaboration with Shanghai Reigncom Biotechnology to Bring Novel Infectious Disease Diagnostic Products to the China Market

March 29, 2021 –

NanoPin Technologies (New Orleans, Louisiana, USA) announces the establishment of a strategic partnership with Shanghai Reigncom Biotechnology Co., Ltd. (Shanghai, China). NanoPin and Reigncom will work together to commercialize NanoPin's high-sensitivity and high-specificity infectious disease detection technology on Reigncom's RZ-500 ultra-high performance liquid chromatography tandem mass spectrometry detection system. This collaboration will promote the development of mass spectrometry-based infectious disease blood detection technologies throughout China, with initial applications addressing the global tuberculosis (TB) epidemic.

Dr. Thomas Tombler, CEO of NanoPin stated that "We are very excited to work with Shanghai Reigncom Biotechnology in bringing NanoPin's novel infectious disease diagnostic platform technology to the China market. NanoPin's tuberculosis assay is a rapid and highly sensitive test for active TB which does not require sputum or culture and is able to detect all types of TB in all patient cohorts including infants. We are able to finally address the critical unmet needs for TB and greatly reduce the burden of this disease in China."

NanoPin's diagnostic platform technology originated in the research group of Dr. Tony Hu, Professor and Weatherhead Presidential Chair of Tulane University, who commented that "The collaboration between NanoPin and Reigncom will certainly strengthen the translational power of our platform. We look forward to working with the team in Shanghai and other partners to speed up the commercialization and serving our communities as early as possible".

Reigncom is at the forefront of enabling mass spectrometry-based diagnostics for clinical use and is led by Founder and Chairman, Mr. Weiqi Li, who stated that "Existing tuberculosis diagnosis solutions are simply but not sufficient and precise. The infected person can only know whether they are infected when they take a chest radiograph. The tuberculosis mass spectrometry method will enable patients to see the diagnostic report before they develop symptoms, enabling early detection and early treatment. This cooperation with NanoPin is not only of great significance for the screening and diagnosis of domestic tuberculosis and infectious diseases, but also marks the beginning of nanotechnologies in diagnostics in China."

Dr. Xiaolei Xie, Chief Scientific Officer of Shanghai Reigncom and CEO of Shanghai Ruizhi Technology, added that "China is one of the countries with the most tuberculosis patients.

According to CDC data, there are approximately 550 million people infected. The cooperation with NanoPin will develop a diagnostic product that is different from existing methods in China. Through blood mass spectrometry detection, it is possible to quickly and accurately diagnose active tuberculosis patients, so as to achieve precise treatment of the patients”.

About NanoPin Technologies, Inc.

At NanoPin Technologies, our mission is to advance infectious disease diagnosis and improve patient care using novel diagnostic platforms that produce rapid and accurate results from patient samples. Our versatile platforms address critical needs for current infectious disease epidemics such as tuberculosis (historically the leading cause of death from infectious disease worldwide), HIV, and COVID-19. For more information about NanoPin and its diagnostic platforms, please contact Dr. Thomas Tombler at ttombler@nanopintech.com

About Shanghai Reigncom Biotechnology, Co., Ltd.

Shanghai Reigncom is a high-tech enterprise specializing in the research and development, production and sales of medical diagnostic instruments and equipment, in vitro diagnostic reagents, and related technical services. The company has developed clinical biochemistry diagnostic products platform and established an industry-leading mass spectrometry instrument development platform in cooperation with the world’s top 500 companies. Reigncom has also established subsidiaries and research sites dedicated to the development of mass spectrometry reagents in Silicon Valley, USA and Shanghai, China. Reigncom has nearly one hundred medical device product registration certificates and CE certifications.

###